Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation |
|---|
| Name (Synonyms) | Correlation | |
|---|---|---|
| D017719 | Diabetic Foot NIH | 1.00 |
| D016523 | Foot Ulcer NIH | 1.00 |
| D014456 | Ulcer NIH | 0.30 |
| Name (Synonyms) | Correlation |
|---|
Navigate: Correlations HPO
There is one clinical trial.
This is a two-part phase 1/2A study performed in diabetic foot ulcer (DFU) patients with chronic non-healing wounds to investigate the safety and efficacy of AUP1602-C.
Description: Incidence of adverse events (AEs) and potential dose-limiting toxicities (DLTs) for safety, low, medium, and high dose cohorts of single and repeatedly administered AUP1602-C
Measure: Incidence of adverse events (AEs) and potential dose-limiting toxicities (DLTs) Time: 4 weeksDescription: • Incidence of AEs
Measure: Incidence of Treatment-Emergent Adverse Events Time: 6 monthsDescription: Percentage (%) of patients with a target ulcer achieving complete wound closure Percentage (%) of wound size reduction (wound area measurements in cm^2)
Measure: Incidence of Wound Closure Time: 6 monthsDescription: Percentage (%) of wound area (cm^2) reduction Percentage (%) of wound depth (mm) reduction Percentage (%) of wound volume (mm^3) reduction Measurements will be aggregated: Wound are and depth will be used to calculate wound volume.
Measure: Incidence of Wound Closure Time: 6 monthsDescription: Percentage (%) of patients with ulcer recurrence
Measure: Incidence of ulcer recurrence Time: 6 monthsDescription: Proportion of patients with local wound infections related to the target ulcer
Measure: Incidence of Wound Infections Time: 6 monthsDescription: Number of patients with local surgical procedures Incidence of amputations (minor or major) related to the target ulcer
Measure: Incidence of surgical procedures Time: 6 monthsDescription: Change from baseline in health-related quality is assessed according to EuroQoL-5 Dimensions (EQ-5D-5L) patient quesionnaire. Five single-item dimensions (mobility, self-care, usual activities, pain/discomfort and anxiety/depression) are assessed. Result of the questionnaire is scored from 0 (worst health imaginable) to 100 (best health imaginable).
Measure: Changes in Quality of Life according to EQ-5D-5L Time: 6 monthsDescription: Change from baseline in health-related quality is assessed according to Dermatology Life Quality Index (DLQI). It consists of 10 questions, where each question is scored from 0 (not affected at all) to 3 (very much affected). The DLQI score will be calculated as the sum of the 10 individual question scores and ranges from 0 to 30, with lower scores indicating better quality of life.
Measure: Changes in Quality of Life according to DLQI Time: 6 monthsDescription: Change from baseline in patient's pain intensity according to a numerical Visual Analog Scale (VAS) ranging from 0 = no pain to 10= worst imaginable pain.
Measure: Changes in pain assessment according to VAS Time: 6 monthsDescription: Incidence of abnormal vital signs Incidence of abnormal ECG data Incidence of abnormal echocardiogram data Incidence of abnormal ophthalmoscopy data Incidence of abnormal physical examination findings Incidence of abnormal laboratory data
Measure: Incidence of Adverse Events Time: 6 monthsDescription: Assessment of biodistribution and shedding (yes / no)
Measure: Incidence of bacteria distribution Time: 6 monthsAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports